On February 2, 2022 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, reported that it will participate in two upcoming healthcare conferences (Press release, Mirati, FEB 2, 2022, View Source [SID1234607645]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wednesday, February 9 at 12:30 p.m. ET / 9:30 a.m. PT at the Guggenheim Healthcare Talks: Oncology Conference. James Christensen, Ph.D., chief scientific officer, will represent the company in a fireside chat at the conference.
Friday, February 18 at 12:00 p.m. ET / 9:00 a.m. PT at the SVB Leerink 2022 Global Healthcare Conference. David Meek, chief executive officer, will represent the company in a fireside chat at the conference.
Investors and the general public are invited to listen to a live webcast of the session through the "Investors and Media" section on Mirati.com. A replay of the webcast will be made available following the event.